The Cookie Jar is a Facebook group run by FHI 360’s Accelerating Progress in Communities (APC 2.0) project to support young women in Botswana in shifting social and gender norms. Members talk about issues like HIV risks, gaps in knowledge about infections and access to treatment. Typically, young women like me do not use HIV services despite risks of infection or violence in relationships. In Botswana, many young women engage in intergenerational and transactional sex. The Cookie Jar provides a place for young women to seek information, find out how to get care and receive peer support.
Tagged: HIV prevention
Put a ring on it: Four reasons to make the dapivirine ring an HIV prevention option for women and girlsWritten by
While much progress has been made to end the HIV epidemic, not enough has been done to put the power of prevention directly in women’s hands. The dapivirine ring, a flexible silicone ring inserted monthly into the vagina, can change this. If approved by regulators, the ring would be the first discreet, long-acting HIV prevention tool available specifically for women. The ring would complement daily oral HIV pre-exposure prophylaxis (PrEP) as another biomedical tool in the fight against HIV.
Recent evidence suggests significant acceptability of and demand for vaginal rings as a drug-delivery platform among women who used the dapivirine ring during clinical trials — and also among policymakers and other stakeholders in countries with a high HIV burden. To better understand these perspectives, the OPTIONS Consortium interviewed policymakers, implementers and civil society leaders in seven sub-Saharan African countries about possibilities for introduction and scale-up of the dapivirine ring. An analysis of the interviews shows widespread enthusiasm for the ring as part of comprehensive HIV prevention programming.
Sexual and reproductive health, which includes access to family planning and HIV prevention and treatment, is increasingly being linked to progress across all areas of development. As the United Nations Open Working Group (OWG) on Sustainable Development comes closer to finalizing the post-2015 global development goals, a growing crescendo of voices is commenting on where we stand with regard to meeting the sexual and reproductive health needs of the world’s girls, women and couples and is offering ideas on how to move ahead. We are also seeing important shifts in policy.
There are many examples that illustrate the lively dialogue that is now happening on sexual and reproductive health.
An article in the journal Contraception acknowledges that although significant, measurable progress on sexual and reproductive health has been made in the two decades since the International Conference on Population and Development (ICPD), momentum on key areas of family planning has slowed in recent years.
New commentaries in the Bulletin of the World Health Organization and The Lancet summarize the evidence for why universal access to family planning should be a key component of the post-2015 development agenda. Additional commentaries in The Lancet and Global Health: Science and Practice Journal offer actionable recommendations for meeting global demand for family planning. Finally, Womenatthecenter.org, an exciting new website, is sharing “inspiring, interconnected stories of women’s reproductive health and rights, empowerment and environmental sustainability.”
The latest figures on HIV infections, as reported this week by the Joint United Nations Programme on HIV/AIDS (UNAIDS), revealed an impressive 33 percent reduction in new infections among adults and children since 2001. To continue down the road to success, future efforts must address the gender inequities that contribute to the disproportionate impact of HIV and AIDS on women and girls.
More than half of the 35 million people living with HIV are women. In sub-Saharan Africa, almost 60 percent of people living with HIV are women. Young women between ages 15 to 24 are at highest risk of and most vulnerable to HIV infection. Closer to home, black women in the United States remain at high risk for HIV infection, and HIV-related illness is now one of the leading causes of death among black women between ages 25 to 34.
Gender inequity is a key driver of the epidemic, making women more vulnerable to HIV in many ways.
May 18th is HIV Vaccine Awareness Day (HVAD), an annual observance that recognizes the contributions of thousands of volunteers, community members, health professionals, scientists, and experts in the HIV/AIDS field who are committed to working together to find an HIV vaccine. This year, we acknowledge the participation of thousands of trial volunteers who have made the research possible, and we highlight recent progress that gives us hope that controlling this epidemic is within our reach.
Great strides have been made in the three decades since the U.S. Centers for Disease Control and Prevention (CDC) reported the first cases of what we know today as HIV/AIDS. What was considered a death sentence in the early 80s is now a manageable chronic condition for those living with HIV who have access to medications. However, about 30 million people globally have died as a result of HIV/AIDS, and 50,000 Americans still become infected every year. Despite the profound impact this disease continues to have in our communities, new developments in HIV prevention efforts inspire us with the hopeful expectation of an AIDS-free generation.
Recent advances in biomedical HIV prevention research have included microbicides and pre-exposure prophylaxis (PrEP). Microbicides are gels or creams that both women and men can use topically to prevent the sexual transmission of HIV. Other products, such as films, suppositories, vaginal rings or sponges, are also being developed to release the active ingredients in the body over time. The microbicides that have proven to be partially effective to date contain an anti-HIV drug known as Tenofovir. PrEP is an approach that involves the use of oral anti-HIV drugs taken by uninfected individuals to prevent HIV infection if exposed to the virus. One drug, known as Truvada, has been shown to be effective in some populations. Consequently, on May 10, an advisory committee recommended that the U.S. Food and Drug Administration approve the use of Truvada as part of PrEP to prevent sexually transmitted HIV-1 infection. While both of these prevention strategies have varying degrees of protection against HIV, adding a safe, effective and durable vaccine to the combination of available prevention tools remains our best hope to ending the pandemic.
Scientists believe that it will take more than one approach to control the spread of HIV in the world. PrEP, microbicides and HIV vaccines, along with other proven prevention methods such as the regular use of condoms, are essential components of a comprehensive approach to global HIV prevention efforts. But, the success of the research in all these areas greatly depends on community participation and involvement as well as establishing trusting relationships within the communities most affected by HIV.
Collaboration among scientists, community leaders, and advocacy groups is essential for the fight against HIV/AIDS. In January 2012, the Be The Generation Bridge (BTG Bridge) program was funded by the U.S. National Institute of Allergy and Infectious Diseases to help increase awareness and understanding of biomedical HIV prevention research, including HIV vaccines. To learn more about this research and view community profile videos, visit www.youtube.com/bethegeneration.